nach oben

Current Bladder Dysfunction Reports

Erschienen in:

15.01.2024 | REVIEW

Gene Therapy and Overactive Bladder

verfasst von: Stephen Patrick, Eric Rovner

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Within the last decade, a number of gene therapies have been developed as a treatment option for monogenic diseases. Overactive bladder is a multifactorial syndrome with likely many underlying causes and regulatory components. The goal of this paper is to review current gene therapy in and outside of the genitourinary system, review the pathophysiology and genetics of OAB, and discuss recent advances in application of this technology for OAB treatment.

Recent Findings

Various genes have been found to be upregulated in OAB patients including receptors involved in purinergic signaling, gap junctions between detrusor smooth muscle cells, proteins involved in detrusor myocyte cytoskeletal dynamics, cholinergic receptors, and some types of membrane channels. Fewer genes are downregulated but include receptors in purinergic signaling and a channel critical for detrusor smooth muscle cell relaxation. Results of a recent phase 2 trial exploiting a gene coding for a portion of a potassium channel suggest that gene therapy may have emerging relevance in OAB therapy.

Summary

OAB is a syndrome, and the pathophysiology is incompletely understood but likely is due to a combination of altered afferent signaling at the level of the bladder modified by a constant hyper- or hypo-excitability of the detrusor myocyte. Understanding the complex pathways underlying OAB as well as the related genetic components of the normal and abnormal bladder may provide novel therapeutic options for this widespread condition.

Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–4. https://doi.org/10.1002/nau.22609.CrossRefPubMed

Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7. https://doi.org/10.1002/nau.22295.CrossRefPubMed

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14. https://doi.org/10.1016/j.eururo.2006.09.019. discussion 14-5.CrossRefPubMed

Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526-532.e18. https://doi.org/10.1016/j.urology.2009.06.096.CrossRefPubMed

• Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63. https://doi.org/10.1097/ju.0000000000000309. AUA/SUFU OAB Guideline reflecting relevant literature published through October 2018.CrossRefPubMed

Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265(5):609–13.CrossRefPubMed

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Intern Med. 2019;179(8):1084–93. https://doi.org/10.1001/jamainternmed.2019.0677.CrossRefPubMedPubMedCentral

Peters KM, Killinger KA, Gilleran JP, Bartley J, Wolfert C, Boura JA. Predictors of reoperation after sacral neuromodulation: a single institution evaluation of over 400 patients. Neurourol Urodyn. 2017;36(2):354–9. https://doi.org/10.1002/nau.22929.CrossRefPubMed

Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal study of leadless tibial nerve stimulation with eCoin® for urgency urinary incontinence: an open-label, single arm trial. J Urol. 2021;206(2):399–408. https://doi.org/10.1097/ju.0000000000001733.CrossRefPubMed

10.

Chapple C, Sievert K-D, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56. https://doi.org/10.1016/j.eururo.2013.04.001.CrossRefPubMed

11.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93. https://doi.org/10.1016/j.juro.2012.12.022.CrossRefPubMed

12.

Scheller EL, Krebsbach PH. Gene therapy: design and prospects for craniofacial regeneration. J Dent Res. 2009;88(7):585–96. https://doi.org/10.1177/0022034509337480.CrossRefPubMedPubMedCentral

13.

Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. https://doi.org/10.1038/s41392-021-00487-6.CrossRefPubMedPubMedCentral

14.

Anderson WF. Human gene therapy. Science. 1992;256(5058):808–13. https://doi.org/10.1126/science.1589762.CrossRefPubMedADS

15.

John Wiley and Sons LTD, Online. 2023. https://a873679.fmphost.com/fmi/webd/GTCT. Accessed 1/9/24

16.

Cellular & Gene Prodcuts. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products (2023). Accessed 9/27/2023 2023.

17.

Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706–18. https://doi.org/10.1056/NEJMoa2211644.CrossRefPubMed

18.

Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–25. https://doi.org/10.1056/NEJMoa2113708.CrossRefPubMed

19.

Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–93. https://doi.org/10.1016/s1474-4422(21)00001-6.CrossRefPubMed

20.

Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2019;126(9):1273–85. https://doi.org/10.1016/j.ophtha.2019.06.017.CrossRefPubMed

21.

Guide SV, Gonzalez ME, Bagci IS, Agostini B, Chen H, Feeney G, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2211–9. https://doi.org/10.1056/NEJMoa2206663.CrossRefPubMed

22.

• Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107–17. https://doi.org/10.1016/s1470-2045(20)30540-4. First FDA-approved gene therapy in the genitourinary system demonstrating reduction in recurrence of bladder cancer after instillation of adenovirus containing interferon alpha-2b.

23.

Keay SK, Birder LA, Chai TC. Evidence for bladder urothelial pathophysiology in functional bladder disorders. Biomed Res Int. 2014;2014:865463. https://doi.org/10.1155/2014/865463.CrossRefPubMedPubMedCentral

24.

Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50(6A Suppl):57–67. https://doi.org/10.1016/s0090-4295(97)00591-8. discussion 8-73.CrossRefPubMed

25.

Al-Ghazo MA, Ghalayini IF, Al-Azab R, Hani OB, Matani YS, Haddad Y. Urodynamic detrusor overactivity in patients with overactive bladder symptoms. Int Neurourol J. 2011;15(1):48–54. https://doi.org/10.5213/inj.2011.15.1.48.CrossRefPubMedPubMedCentral

26.

Burgers R, de Jong TP, Visser M, Di Lorenzo C, Dijkgraaf MG, Benninga MA. Functional defecation disorders in children with lower urinary tract symptoms. J Urol. 2013;189(5):1886–91. https://doi.org/10.1016/j.juro.2012.10.064.CrossRefPubMed

27.

Carter D, Beer-Gabel M. Lower urinary tract symptoms in chronically constipated women. Int Urogynecol J. 2012;23(12):1785–9. https://doi.org/10.1007/s00192-012-1812-1.CrossRefPubMed

28.

Wu C, Sui GP, Fry CH. Purinergic regulation of guinea pig suburothelial myofibroblasts. J Physiol. 2004;559(Pt 1):231–43. https://doi.org/10.1113/jphysiol.2004.067934.CrossRefPubMedPubMedCentral

29.

O’Reilly BA, Kosaka AH, Knight GF, Chang TK, Ford AP, Rymer JM, et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol. 2002;167(1):157–64.CrossRefPubMed

30.

Ray FR, Moore KH, Hansen MA, Barden JA. Loss of purinergic P2X receptor innervation in human detrusor and subepithelium from adults with sensory urgency. Cell Tissue Res. 2003;314(3):351–9. https://doi.org/10.1007/s00441-003-0788-z.CrossRefPubMed

31.

Fry CH, Ikeda Y, Harvey R, Wu C, Sui GP. Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology. 2004;63(3 Suppl 1):24–31. https://doi.org/10.1016/j.urology.2003.10.031.CrossRefPubMed

32.

Neuhaus J, Pfeiffer F, Wolburg H, Horn L-C, Dorschner W. Alterations in connexin expression in the bladder of patients with urge symptoms. BJU Int. 2005;96(4):670–6. https://doi.org/10.1111/j.1464-410X.2005.05703.x.CrossRefPubMed

33.

Maake C, Landman M, Wang X, Schmid DM, Ziegler U, John H. Expression of smoothelin in the normal and the overactive human bladder. J Urol. 2006;175(3 Pt 1):1152–7. https://doi.org/10.1016/s0022-5347(05)00315-0.CrossRefPubMed

34.

Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84(3):935–86. https://doi.org/10.1152/physrev.00038.2003.CrossRefPubMed

35.•

Hristov KL, Afeli SA, Parajuli SP, Cheng Q, Rovner ES, Petkov GV. Neurogenic detrusor overactivity is associated with decreased expression and function of the large conductance voltage- and Ca(2+)-activated K(+) channels. PLoS One. 2013;8(7):e68052. https://doi.org/10.1371/journal.pone.0068052. Detrusor overactivity is associated with decreased BK channel expression.

36.

Mukerji G, Yiangou Y, Corcoran SL, Selmer IS, Smith GD, Benham CD, et al. Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations. BMC Urol. 2006;6:6. https://doi.org/10.1186/1471-2490-6-6.CrossRefPubMedPubMedCentral

37.

Tae BS, Park TY, Jeon BJ, Chung H, Lee YH, Park JY, et al. Seasonal variation of overactive bladder symptoms in female patients. Int Neurourol J. 2019;23(4):334–40. https://doi.org/10.5213/inj.1938078.039.CrossRefPubMedPubMedCentral

38.

Roberts MWG, Sui G, Wu R, Rong W, Wildman S, Montgomery B, et al. TRPV4 receptor as a functional sensory molecule in bladder urothelium: stretch-independent, tissue-specific actions and pathological implications. Faseb j. 2020;34(1):263–86. https://doi.org/10.1096/fj.201900961RR.CrossRefPubMed

39.

Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006;176(1):367–73. https://doi.org/10.1016/s0022-5347(06)00563-5.CrossRefPubMed

40.•

Isali I, McClellan P, Wong TR, Sun C, Stout AC, Schumacher FR, et al. A systematic review and in silico study of potential genetic markers implicated in cases of overactive bladder. Am J Obstet Gynecol. 2023;228(1):36–47.e3. https://doi.org/10.1016/j.ajog.2022.07.044. Review article analyzing upregulated OAB genes revealing overlap in calcium signaling pathways and neuroactive ligand-receptor interaction.

41.

Ohi Y, Yamamura H, Nagano N, Ohya S, Muraki K, Watanabe M, et al. Local Ca(2+) transients and distribution of BK channels and ryanodine receptors in smooth muscle cells of guinea-pig vas deferens and urinary bladder. J Physiol. 2001;534(Pt. 2):313–26. https://doi.org/10.1111/j.1469-7793.2001.t01-3-00313.x.CrossRefPubMedPubMedCentral

42.

Latorre R, Miller C. Conduction and selectivity in potassium channels. J Membr Biol. 1983;71(1–2):11–30. https://doi.org/10.1007/bf01870671.CrossRefPubMed

43.

Tseng-Crank J, Foster CD, Krause JD, Mertz R, Godinot N, DiChiara TJ, et al. Cloning, expression, and distribution of functionally distinct Ca(2+)-activated K+ channel isoforms from human brain. Neuron. 1994;13(6):1315–30. https://doi.org/10.1016/0896-6273(94)90418-9.CrossRefPubMed

44.

•• Rovner E, Chai TC, Jacobs S, Christ G, Andersson KE, Efros M, et al. Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. Neurourol Urodyn. 2020;39(2):744–53. https://doi.org/10.1002/nau.24272. Intravesical administration or intradetrusor injection of URO-902 is safe and not associated with any significant adverse events with clinical significance in reduction of urgency episodes and number of voids in those receiving injection.

45.

• Andersson KE, Christ GJ, Davies KP, Rovner ES, Melman A. Gene therapy for overactive bladder: A review of BK-channel α-subunit gene transfer. Ther Clin Risk Manag. 2021;17:589–99. https://doi.org/10.2147/tcrm.S291798. Comprehensive review of BK-channel and studies in ED as well as URO-902.

46.

Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: Preliminary results. Eur Urol. 2005;48(2):314–8. https://doi.org/10.1016/j.eururo.2005.05.005.CrossRefPubMed

47.

Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. hMaxi-K gene transfer in males with erectile dysfunction: Results of the first human trial. Hum Gene Ther. 2006;17(12):1165–76. https://doi.org/10.1089/hum.2006.17.1165.CrossRefPubMed

48.

Arun N. Treatment of erectile dysfunction with hMaxi-K gene transfer: Safety report from phase IIA study. Eur Urol. 2018;12(2).

49.

•• Kenneth Peters EE, Susan Kalota, Kaiser Robertson, Sijian Ge, Jingmei Lu, Hanh Badger, Salim Mujais. Long-term efficacy and safety of URO-902 (PVAX/HSLO) in women with overactive bladder and urge urinary incontinence: Final results of a phase 2A trial. . Journal of Urology. 2023;209:e1184. Larger trial demonstrating reduced number of voids per day and urgency episodes at 12 weeks after intradetrusor injection of URO-902.

Titel: Gene Therapy and Overactive Bladder
verfasst von: Stephen Patrick
Eric Rovner
Publikationsdatum: 15.01.2024
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 1/2024
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-023-00733-3

Use and Outcomes of Botulinum Toxin A for Both Neurogenic and Non-neurogenic Voiding Dysfunction in the Pediatric Patient

In the Era of Holmium Laser Enucleation of the Prostate Is Preoperative Urodynamics Required for Men in Urinary Retention?

Review

Overactive Bladder: the Patient Perspective

REVIEW

Chronic Eosinophilic Cystitis: Up to Date Evidence Review

REVIEW

Urinary Biomarkers of Detrusor Underactivity

Review

Urodynamics in the Transplant Population

REVIEW

Neu im Fachgebiet Urologie

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

14.01.2025
Nierenkarzinom
Nachrichten

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Auf weichem Fahrradsattel ist nicht gut Kinder zeugen

14.01.2025
Erektile Dysfunktion
Nachrichten

Männer, die sich gern sportlich verausgaben, riskieren möglicherweise, fürs Vaterwerden nicht genug Kräfte übrig zu haben. In einer Studie fanden sich dafür zwar allenfalls schwache Anzeichen. Es gab jedoch eine Ausnahme.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

14.01.2025
Prostatakarzinom
Nachrichten

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Gene Therapy and Overactive Bladder

Abstract

Purpose of Review

Recent Findings

Summary

Weitere Artikel der Ausgabe 1/2024

Use and Outcomes of Botulinum Toxin A for Both Neurogenic and Non-neurogenic Voiding Dysfunction in the Pediatric Patient

In the Era of Holmium Laser Enucleation of the Prostate Is Preoperative Urodynamics Required for Men in Urinary Retention?

Overactive Bladder: the Patient Perspective

Chronic Eosinophilic Cystitis: Up to Date Evidence Review

Urinary Biomarkers of Detrusor Underactivity

Urodynamics in the Transplant Population

Neu im Fachgebiet Urologie

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Auf weichem Fahrradsattel ist nicht gut Kinder zeugen

Vorteile für Androgenentzug plus Androgenrezeptorblockade

Update Urologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten